Surveillance of pneumococcal diseases in Central and Eastern Europe

References

• Black RE, Cousens S, Johnson HL, Lawn JE, Rudan I, Bassani DG, Jha P, Campbell H, Walker CF, Cibulskis R, et al. Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet 2010; 375:1969-87; PMID:20466419; http://dx.doi.org/10.1016/S0140-6736(10)60549-1
   PubMed Web of Science ®Google Scholar
• O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, Lee E, Mulholland K, Levine OS, Cherian T. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009; 374:893-902; http://dx.doi.org/10.1016/S0140-6736(09)61204-6
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases, 13th edn. 2015. Available at: www.cdc.gov/vaccines/pubs/pinkbook/downloads/pneumo.pdf
   Google Scholar
• Ludwig E, Bonanni P, Rohde G, Sayiner A, Torres A. The remaining challenges of pneumococcal disease in adults. Eur Respir Rev 2012; 21:57-65; PMID:22379175; http://dx.doi.org/10.1183/09059180.00008911
   PubMedGoogle Scholar
• PNEUMOVAX® 23 (pneumococcal vaccine polyvalent) US Prescribing Information.
   Google Scholar
• Prevenar 13® (pneumococcal 13-valent conjugate vaccine) Summary of Product Characteristics. Kent, UK: Pfizer Ltd
   Google Scholar
• Veenhoven RH, Bogaert D, Schilder AGM, Rijkers GT, Uiterwaal CSPM, Kiezebrink HH, van Kempen MJ, Dhooge IJ, Bruin J, Ijzerman EP, et al. Nasopharyngeal pneumococcal carriage after combined pneumococcal conjugate and polysaccharide vaccination in children with a history of recurrent acute otitis media. Clin Infect Dis 2004; 39:911-9; PMID:15472839; http://dx.doi.org/10.1086/422651
   PubMed Web of Science ®Google Scholar
• Pebody RG, Leino T, Nohynek H, Hellenbrand W, Salmaso S, Ruutu P. Pneumococcal vaccination policy in Europe. Eurosurveill 2005; 10(9):174-8.
   Google Scholar
• Bogaert D, de Groot R, Hermans PWM. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis 2004; 4(3):144-54; PMID:14998500; http://dx.doi.org/10.1016/S1473-3099(04)00938-7
   PubMed Web of Science ®Google Scholar
• Cardozo DM, Nascimento-Carvalho CM, Souza FR, Silva NM. Nasopharyngeal colonization and penicillin resistance among pneumococcal strains: a worldwide 2004 update. Braz J Infect Dis 2006; 10:293-303; PMID:17293914; http://dx.doi.org/10.1590/S1413-86702006000400015
   PubMedGoogle Scholar
• Regev-Yochay G, Raz M, Dagan R, Porat N, Shainberg B, Pinco E, Keller N, Rubinstein E. Nasopharyngeal carriage of Streptococcus pneumoniae by adults and children in community and family settings. Clin Infect Dis 2004; 38:632-39; PMID:14986245; http://dx.doi.org/10.1086/381547
   PubMed Web of Science ®Google Scholar
• Chi DH, Hendley JO, French P, Arango P, Hayden FG, Winther B. Nasopharyngeal reservoir of bacterial otitis media and sinusitis pathogens in adults during wellness and viral respiratory illness. Am J Rhinol 2003; 17(4):209-14; PMID:12962190
   PubMedGoogle Scholar
• Sandgren A, Sjöström K, Olsson-Liljequist B, Christensson B, Samuelsson A, Kronvall G, Henriques Normark B. Effect of clonal and serotype-specific properties on the invasive capacity of Streptococcus pneumoniae. J Infect Dis 2004; 189:785-96; PMID:14976594; http://dx.doi.org/10.1086/381686
   PubMed Web of Science ®Google Scholar
• Feldman C, Anderson R. Recent advances in our understanding of Streptococcus pneumoniae infection. F1000Prime Rep 2014; 6:82; PMID:25343039; http://dx.doi.org/10.12703/P6-82
   PubMedGoogle Scholar
• Song JY, Nahm MH, Moseley MA. Clinical implications of pneumococcal serotypes: invasive disease potential, clinical presentations, and antibiotic resistance. J Korean Med Sci 2013; 28:4-15; PMID:23341706; http://dx.doi.org/10.3346/jkms.2013.28.1.4
   PubMed Web of Science ®Google Scholar
• Weinberger DM, Harboe ZB, Sanders EAM, Ndiritu M, Klugman KP, Ruckinger S, Dagan R, Adegbola R, Cutts F, Johnson HL, et al. Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis. Clin Infect Dis 2010; 51:692-9; PMID:20715907; http://dx.doi.org/10.1086/655828
   PubMed Web of Science ®Google Scholar
• Ferreira DM, Jambo KC, Gordon SB. Experimental human pneumococcal carriage models for vaccine research. Trends Microbiol 2011; 19:464-70; PMID:21784641; http://dx.doi.org/10.1016/j.tim.2011.06.003
   PubMed Web of Science ®Google Scholar
• Feikin DR, Klugman KP. Historical changes in pneumococcal serogroup distribution: implications for the era of pneumococcal conjugate vaccines. Clin Infect Dis 2002; 35:547-55; PMID:12173128; http://dx.doi.org/10.1086/341896
   PubMed Web of Science ®Google Scholar
• Feikin DR, Klugman KP, Facklam RR, Zell ER, Schuchat A, Whitney CG. Increased prevalence of pediatric pneumococcal serotypes in elderly adults. Clin Infect Dis 2005; 41:481-7; PMID:16028155; http://dx.doi.org/10.1086/432015
   PubMed Web of Science ®Google Scholar
• Guevara M, Barricarte A, Gil-Setas A, Garcia-Irure JJ, Beristain X, Torroba L, Petit A, Polo Vigas ME, Aguinaga A, Castilla J. Changing epidemiology of invasive pneumococcal disease following increased coverage with the heptavalent conjugate vaccine in Navarre, Spain. Clin Microbiol Infect 2009; 15:1013-9; PMID:19673968; http://dx.doi.org/10.1111/j.1469-0691.2009.02904.x
   PubMed Web of Science ®Google Scholar
• Kellner JD, Vanderkooi OG, MacDonald J, Church DL, Tyrrell GJ, Scheifele DW. Changing epidemiology of invasive pneumococcal disease in Canada, 1998-2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study. Clin Infect Dis 2009; 49:205-12; PMID:19508165; http://dx.doi.org/10.1086/599827
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control. Surveillance of invasive bacterial diseases in Europe, 2011. Stockholm: ECDC, 2013.
   Google Scholar
• Improving global health by preventing pneumococcal disease. Report from the All-Party Parliamentary Group on Pneumococcal Disease Prevention in the Developing World. Available at: www.gavi.org/Library/Documents/AMC/All-Party-Parlimentary-Group-on-Pneumococcal-Disease-Report
   Google Scholar
• Felmingham D, Cantón R, Jenkins SG. Regional trends in β-lactam, macrolide, fluoroquinolone and telithromycin resistance among Streptococcus pneumoniae isolates 2001-2004. J Infect 2007; 55:111-8; PMID:17568680; http://dx.doi.org/10.1016/j.jinf.2007.04.006
   PubMed Web of Science ®Google Scholar
• Dagan R, Klugman KP. Impact of conjugate pneumococcal vaccines on antibiotic resistance. Lancet Infect Dis 2008; 8(12):785-95; PMID:19022193; http://dx.doi.org/10.1016/S1473-3099(08)70281-0
   PubMed Web of Science ®Google Scholar
• Fenoll A, Granizo JJ, Aguilar L, Giménez MJ, Aragoneses-Fenoll L, Hanquet G, Casal J, Tarragó D. Temporal trends of invasive Streptococcus pneumoniae serotypes and antimicrobial resistance patterns in Spain from 1979 to 2007. J Clin Microbiol 2009; 47:1012-20; PMID:19225097; http://dx.doi.org/10.1128/JCM.01454-08
   PubMed Web of Science ®Google Scholar
• Muñoz-Almagro C, Esteva C, Fernandez de Sevilla M, Selva L, Gene A, Pallares R. Emergence of invasive pneumococcal disease caused by multidrug-resistant serotype 19A among children in Barcelona. J Infect 2009; 59:75-82; http://dx.doi.org/10.1016/j.jinf.2009.05.012
   PubMed Web of Science ®Google Scholar
• McElligott M, Vickers I, Carrferkey M, Cunney R, Humphreys H. Non-invasive pneumococcal serotypes and antimicrobial susceptibilities in a paediatric hospital in the era of conjugate vaccines. Vaccine 2014; 32:3495-500; PMID:24795223; http://dx.doi.org/10.1016/j.vaccine.2014.04.047
   PubMed Web of Science ®Google Scholar
• Ben-Shimol S, Greenberg D, Givon-Lavi N, Schlesinger Y, Somekh E, Aviner S, Miron D, Dagan R. Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children. Vaccine 2014; 32:3452-9; PMID:24690148; http://dx.doi.org/10.1016/j.vaccine.2014.03.065
   PubMed Web of Science ®Google Scholar
• Ben-Shimol S, Givon-Lavi N, Leibovitz E, Raiz S, Greenberg D, Dagan R. Near-elimination of otitis media caused by 13-valent pneumococcal conjugate vaccine (PCV) serotypes in southern Israel shortly after sequential introduction of 7-valent/13-valent PCV. Clin Infect Dis 2014; 59:1724-32; PMID:25159581; http://dx.doi.org/10.1093/cid/ciu683
   PubMed Web of Science ®Google Scholar
• Angoulvant F, Levy C, Grimprel E, Varon E, Lorrot M, Biscardi S, Minodier P, Dommergues MA, Hees L, Gillet Y, et al. Early impact of 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia in children. Clin Infect Dis 2014; 58:918-24; PMID:24532543; http://dx.doi.org/10.1093/cid/ciu006
   PubMed Web of Science ®Google Scholar
• Steens A, Bergsaker MA, Aaberge IS, Rønning K, Vestrheim DF. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway. Vaccine 2013; 31:6232-8; PMID:24176490; http://dx.doi.org/10.1016/j.vaccine.2013.10.032
   PubMed Web of Science ®Google Scholar
• Azzari C, Resti M. Reduction of carriage and transmission of Streptococcus pneumoniae: the beneficial “side effect” of pneumococcal conjugate vaccine. Clin Infect Dis 2008; 47:997-9; PMID:18781870; http://dx.doi.org/10.1086/591967
   PubMed Web of Science ®Google Scholar
• Simonsen L, Taylor RJ, Young-Xu Y, Haber M, May L, Klugman KP. Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States. MBio 2011; 2:e00309-10; PMID:21264063; http://dx.doi.org/10.1128/mBio.00309-10
   PubMed Web of Science ®Google Scholar
• Moore MR. Update on effectiveness and impact of PCV13 use among US children. Presented at the Advisory Committee on Immunization Practices (ACIP), February 20–21, 2013, Atlanta, Georgia.
   Google Scholar
• Harboe ZB, Dalby T, Weinberger DM, Benfield T, Mølbak K, Slotved HC, Suppli CH, Konradsen HB, Valentiner-Branth P. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. Clin Infect Dis 2014; 59:1066-73; PMID:25034421; http://dx.doi.org/10.1093/cid/ciu524
   PubMed Web of Science ®Google Scholar
• Menéndez R, Torres A, España PP, Pérez-Trallero E, López Hontangas JL, Marco F, et al. Pneumococcal serotypes causing community-acquired pneumonia (CAP) among hospitalized adults in Spain using a new urinary antigen detection (UAD) test. The CAPA study. Presented at ERS Congress 2014.
   Google Scholar
• Grijalva CG, Wunderink RG, Williams D, Zhu Y, Balk R, Fakhran S, et al. Distribution of pneumococcal serotypes detected through urine analysis among us adults hospitalized with pneumonia after introduction of PCV13. Presented at the 9th International Symposium on Pneumococci and Pneumococcal Diseases, 9–13 March 2014, Hyderabad, India [#ISPPD-0225]
   Google Scholar
• Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, van Werkhoven CH, van Deursen AM, Sanders EA, Verheij TJ, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 2015; 372:1114-25; PMID:25785969
   PubMed Web of Science ®Google Scholar
• Tomczyk S, Bennett NM, Stoecker C, Gierke R, Moore MR, Whitney CG, Hadler S, Pilishvili T. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2014; 63:822-5; PMID:25233284
   PubMed Web of Science ®Google Scholar
• Huss A, Scott P, Stuck AE, Trotter C, Egger M. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ 2009; 180:48-58; PMID:19124790
   PubMed Web of Science ®Google Scholar
• Leventer-Roberts M, Feldman BS, Brufman I, Cohen-Stavi CJ, Hoshen M, Balicer RD. Effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive disease and hospital-treated pneumonia among people aged 65+: A retrospective case-control study. Clin Infect Dis 2015; 60(10):1472-80; PMID:25669354
   PubMed Web of Science ®Google Scholar
• Musher DM. Editorial commentary: should 13-valent protein-conjugate pneumococcal vaccine be used routinely in adults? Clin Infect Dis 2012; 55(2):265-7; PMID:22495544
   PubMed Web of Science ®Google Scholar
• Jackson LA, Gurtman A, van Cleeff M, Frenck RW, Treanor J, Jansen KU, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B. Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older. Vaccine 2013; 31(35):3594-602; PMID:23688525
   PubMed Web of Science ®Google Scholar
• Pazdiora P. Data presented at the 7^th Pneumo Surveillance Summit, Istanbul, Turkey, 26-27 September 2014.
   Google Scholar
• Hryniewicz W. Surveillance in Poland: BINet experience. Presented at the 7^th Pneumo Surveillance Summit, Istanbul, Turkey, 26-27 September 2014.
   Google Scholar
• Maďarová L, Bottková E, Čamajová J, Klement C, Avdičová M. Data presented at the 7^th Pneumo Surveillance Summit, Istanbul, Turkey, 26-27 September 2014.
   Google Scholar
• Streinu-Cercel A. Data presented at the 7^th Pneumo Surveillance Summit, Istanbul, Turkey, 26-27 September 2014.
   Google Scholar
• Lobzin YV, et al. Serotypes of Streptococcus pneumoniae causing major pneumococcal infections. J Infectol 2013; 5:36-42.
   Google Scholar
• Mayansky N, Alyabieva N, Ponomarenko O, Lazareva A, Katosova L, Ivanenko A, Kulichenko T, Namazova-Baranova L, Baranov A. Serotypes and antibiotic resistance of non-invasive Streptococcus pneumoniae circulating in pediatric hospitals in Moscow, Russia. Int J Infect Dis 2014; 20:58-62; PMID:24462930
   PubMed Web of Science ®Google Scholar
• Kozlov RS, Krechikova OI, Muravyev AA, Mironov KO, Platonov AE, Dunaeva EA, et al. Incidence of community-acquired pneumonia and acute otitis media in children 0-5 years in Russia and role of S. pneumoniae or H. influenzae in the etiology of the diseases. Clin Microbiol Antimicrob Chemother 2013; 15:246-60.
   Google Scholar
• Ceyhan M, Gurler N, Yaman A, Ozturk C, Oksuz L, Ozkan S, Keser M, Salman N, Alhan E, Esel D, et al. Serotypes of Streptococcus pneumoniae isolates from children with invasive pneumococcal disease in Turkey: Baseline evaluation of the introduction of the pneumococcal conjugate vaccine nationwide. Clin Vaccine Immunol 2011; 18:1028-30; PMID:21508171
   PubMed Web of Science ®Google Scholar
• Hasçelik AG, Gürler N, Ceyhan M, Öksüz L, Özakın C, Bayramoğlu G, et al. Serotype prevalence and antibiotic resistance among adult invasive Streptococcus pneumoniae isolates in Turkey, 2005–2011. Presented at the 16th Int Society Infect Dis (ICID) 2014 [#40.023].
   Google Scholar
• Kulcsar A. Data presented at the 7^th Pneumo Surveillance Summit, Istanbul, Turkey, 26-27 September 2014.
   Google Scholar
• World Health Organization (WHO) vaccine-preventable diseases: monitoring system. 2015 global summary. Available at: http://apps.who.int/immunization_monitoring/globalsummary.
   Google Scholar
• Tóthpál A, Dobay O. Vaccine coverage of invasive and carried Streptococcus pneumoniae isolates in Hungary. LAM 2014; 24(4):180-5.
   Google Scholar
• Chernyshova LI, Gilfanova AM, Bondarenko AV, Yakimovitch SA, Yanovska VV, Glushkevich TG. Streptococcus pneumoniae serotypes distribution in nasopharyngeal carriage in healthy children aged 6 months to 5 years old in Ukraine, 2012–2014. Poster presented at the 7th Pneumo Surveillance Summit, Istanbul, Turkey, 26-27 September 2014.
   Google Scholar
• Skoczyńska A, Kuch A, Sadowy E, Waśko I, Markowska M, Ronkiewicz P, Matynia B, Bojarska A, Wasiak K, Gołębiewska A, et al. Recent trends in epidemiology of invasive pneumococcal disease in Poland. Eur J Clin Microbiol Infect Dis 2015; 34(4):779-87; PMID:25475124
   PubMed Web of Science ®Google Scholar
• National Reference Centre for Pneumococcal Diseases, Slovakia
   Google Scholar
• Stock NK, Maly M, Sebestova H, Orlikova H, Kozakova J, Krizova P. The Czech Surveillance System for Invasive Pneumococcal Disease, 2008-2013: A Follow-Up Assessment and Sensitivity Estimation. PLoS One 2015; 10(6):e0131117; PMID:26125583
   PubMed Web of Science ®Google Scholar
• Tambic Andrasevic A. Data presented at the 7th Pneumo Surveillance Summit, Istanbul, Turkey, 26-27 September 2014.
   Google Scholar
• Ceyhan M. Hum Vacc Immunotherapeutics 2016; 12:308-13; http://dx.doi.org/10.1080/21645515.2015.1078952
   Web of Science ®Google Scholar
• Tambic Andrasevic A, Soprek S. Antibiotic resistance surveillance in invasive isolates. In: Tambic Andrasevic A, Tambic T, eds. Antibiotic resistance in Croatia. Zagreb: Croatian Academy of Medical Sciences; 2014:119-32.
   Google Scholar
• ESPID. Short Oral Presentation Session 1 - Epidemiology and Public Health 14 May 2015; 13:30 15:30, 21.
   Google Scholar
• Yeraliyeva LT, Ramazanova BA, Mustafina KK. Developments in national surveillance 2013-2014: Updates on pneumococcal disease from Kazakhstan. Presented at the 7th Pneumo Surveillance Summit, Istanbul, Turkey, 26–27 September 2014.
   Google Scholar
• Kozakova J, Motlova J, Benes C, et al. Invasive pneumococcal disease in the Czech Republic in 2012. Zpravy CEM (SZU, Praha) 2013:22(3):97-104.
   Google Scholar
• Kozakova J, Sebestova H, Krizova P. Invasive pneumococcal disease in the Czech Republic in 2013. Zpravy CEM (SZU, Praha) 2014; 23(3):89-97.
   Google Scholar
• Regional Authority of Public Health (RAPH), Banská Bystrica, Slovakia. Available at: www.vzbb.sk.
   Google Scholar
• Tóthpál A, Dobay O. Expected clinical effectiveness of PCVs in Hungary. Gyermekgyógyászat 2010; 61:188-91.
   Google Scholar
• Tóthpál A, Dobay O. Nasal carriage of Streptococcus pneumoniae among Hungarian children before the wide use of the conjugate vaccine. Acta Microbiologica Et Immunologica Hungarica 2012; 59:107-18; http://dx.doi.org/10.1556/AMicr.59.2012.1.11
   PubMed Web of Science ®Google Scholar
• National Institute of Public Health, Romania.
   Google Scholar
• Ceyhan M, Ozsurekci Y, Gürler N, Ozkan S, Sensoy G, Belet N, Hacimustafaoglu M, Celebi S, Keser M, Dinleyici EC, et al. Distribution of Streptococcus pneumoniae serotypes that cause parapneumonic empyema in Turkey. Clin Vaccine Immunol 2013; 20:972-6; PMID:23637041; http://dx.doi.org/10.1128/CVI.00765-12
   PubMed Web of Science ®Google Scholar
• Tirczka T. Mikrobiológiai Körlevél 2013.No; 3-4. Available at: www.oek.hu/oek.web?to=1303,2129&nid = 104&pid = 3&lang = hun.
   Google Scholar
• Percin D, Altintop YA, Sumerkan B. Ten-year surveillance of invasive Streptococcus pneumoniae isolates in central Turkey prior to the introduction of a conjugate vaccine. J Infect Dev Ctries 2010; 4:560-5; PMID:21045368; http://dx.doi.org/10.3855/jidc.834
   PubMed Web of Science ®Google Scholar
• Yalçın I, Gürler N, Alhan E, Yaman A, Turqut M, Celik U, Akçakaya N, Camcioğlu Y, Diren S, Yildirim B. Serotype distribution and antibiotic susceptibility of invasive Streptococcus pneumoniae disease isolates from children in Turkey, 2001–2004. Eur J Pediatr 2006; 165(9):654-7; http://dx.doi.org/10.1007/s00431-006-0128-x
   PubMed Web of Science ®Google Scholar
• Altun HU, Hascelik G, Gür D, Eser OK. Invasive pneumococci before the introduction of pneumococcal conjugate vaccine in Turkey: antimicrobial susceptibility, serotype distribution, and molecular identification of macrolide resistance. J Chemother 2015; 27:74-9; PMID:24548097; http://dx.doi.org/10.1179/1973947814Y.0000000176
   PubMed Web of Science ®Google Scholar
• Ceyhan M, Gürler N, Ozsurekci Y, et al. Pneumococcal serotypes causing childhood invasive pneumococcal disease in turkey, 2011-2012. Presented at the 9th International Symposium on Pneumococci and Pneumococcal Diseases, >9–13 March 2014, Hyderabad, India [#ISPPD-0546].
   Google Scholar